Figure 5.
The change in coronary stenosis during combination drug and placebo therapy in FATS is related to the change in LDL peak buoyancy: an increase in LDL buoyancy is associated with less coronary stenosis. Patients with FCHL and elevated Lp(a) treated with combination therapy had and increase in buoyancy, while those with hFH did not. Includes subjects treated with placebo. Modified from [14].